Purpose/Objective: New commercial dosimetry systems need careful characterization at several beam energies and beam modalities, since many different photon MV beam modalities are employed in radiotherapy. Such characterizations can furthermore benefit from the comparison with similar, inhouse developed solutions. In this study, basic dosimetric response of the commercial Exradin W1 plastic scintillator detector (PSD) is investigated and compared with an in-house developed PSD system for five different photon MV energies. Both systems employ PSDs similar in design, calibrated using the same method, but differing primarily in the signal detection hardware. Materials and Methods: The two investigated PSD systems were the commercial Exradin W1 (Standard Imaging Inc.) and the in-house developed ME40 system (DTU Nutech). The two PSD systems were compared with respect to calibration, field size dependence and reference dose. Measurements were performed using a Varian TrueBeam linear accelerator for three conventional photon energies (6 MV, 10 MV and 15 MV) and two flattening filter free (6 MV FFF and 10 MV FFF). Both systems were calibrated as outlined in the Exradin W1 product manual, and the Cerenkov light ratio (CLR) calibration coefficients were determined for all five photon energies. Absolute dose calibration was performed for 6 MV only. Concerning field size dependence, output factors were measured for jaw-collimated fields from 2 cm x 2 cm to 40 cm x 40 cm. An IBA FC65-G Farmer chamber and a PTW 31014 PinPoint chamber were used as reference for the output factor measurements. Reference dose to water was measured at 90 cm source-to-surface distance and 10 cm depth for a 10 cm x 10 cm field size and compared with values obtained using the Farmer chamber. Results: The CLR coefficients of both systems were found to be systematically changing with photon beam quality to a maximum difference of 1.1 % (15 MV relative to 6 MV). Changes in response due to field size dependence were as large as 3.3 % for the W1 and 5.4 % for the ME40, biasing the output factor measurements for large fields. The discrepancies were generally largest for the highest beam qualities (10 MV and 15 MV). Measurements of reference dose to water yielded differences up to 1.5 % when compared with the Farmer chamber values for all investigated beam qualities; the largest differences were again seen for 10 MV and 15 MV relative to 6 MV.
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How has IMRT verification practice in the UK changed over the last two years? F. Abolaban 1 , S. Zaman 2 , J. Cashmore 3 , A. Nisbet 4 , C. Clark 5 1 King Abdulaziz University, Nuclear Engineering, Jeddah, Saudi Arabia 2 University of Surrey, Medical Physics, Guildford, United Kingdom 3 Queen Elizabeth Hospital, Medical Physics, Birmingham, United Kingdom 4 Royal Surrey County Hospital, Medical Physics, Guildford, United Kingdom 5 National Physical Laboratory, Medical Physics, Oxford, United Kingdom Purpose/Objective: Uptake of IMRT techniques within the UK has been relatively slow compared to some other countries (in August 2012 13.6% of radiotherapy patients in England received IMRT). Later that year the UK government created a Radiotherapy Innovation Fund (RIF), releasing £23M of funding to centres to increase IMRT capacity. The aim of the fund was to address obstacles to IMRT treatment and reach a goal of treating more than 24% of all radical radiotherapy patients with IMRT. Prior to the announcement of the fund a survey of radiotherapy centres was carried out in 2012 collecting data on uptake, obstacles to implementation, equipment, delivery techniques and verification methods. A repeat survey has been carried out in 2014 to assess the impact of the RIF and also to identify key changes. Materials and Methods: In the summers of 2012 and 2014, an online questionnaire was sent to all 65 UK radiotherapy institutions. The questionnaire covered the background and equipment, treatment planning system, methods of IMRT delivery, planning and quality assurance (QA) time, QA equipment, sites measurement tolerances, workload, and future QA plans. Results: 96.9% (63/65) and 86.2% (56/65) responded in 2012 and 2014, respectively. All centres use 6MV with some use of 10MV (30%) and a few using 8MV (3%) and 15MV (3%). There has been a shift towards more complex treatment planning algorithms with an increase in Monte Carlo based algorithms and a reduction in pencil beam methods. There has also been a significant increase in the use of VMAT (34% to 74%) with a slight reduction in fixed field IMRT (41% to 35% for dynamic and 49% to 41% for step and shoot). In 2012 all centres reported the need to perform physical measurements for verification, dropping to 97% in 2014, being most common in head and neck (84%) and lung SABR (82%). The most commonly used gamma parameters to analyse the measurements is 3%/3mm, however for the more complex plans (H&N and prostate & pelvic node) there has been an increase in the use of 3%/2mm (12% to 20%) and 2%/2mm (0% to 10%), see table 1. In 2012, 94% of these measurements were made by physicists, dropping to 88% in 2014. There has been an increase in the use of software for verification from 63% in 2012 to 95% in 2014, with a simultaneous increase of second dose distribution calculations from 9% to 26%. In 2014 centres cited that they wished to introduce EPID based QA (42%), introduction of more software based verification (48%) and to stopping measurements altogether (25%). Conclusions: There has been a significant increase in the uptake of IMRT techniques within UK centres in recent years, possibly aided by the RIF. VMAT delivery has taken over a significant proportion of step-and-shoot IMRT and also some dynamic fixed gantry IMRT. Whilst the verification workload burden is still considerable for physics staff, there has been a shift towards software based verification to replace physical measurements. Purpose/Objective: Total body irradiation (TBI) is a special radiotherapy technique, used before bone marrow transplant, aiming to deliver a homogeneous dose to the whole body, with an accepted range of dose homogeneity within ±10% of the prescribed dose. The moving couch technique provides dose uniformity due to the application of dynamic TPR. The purpose of this study is to assess the reliability of metaloxide-semiconductor field-effect transistors(MOSFETs) for invivo verification of the delivered dose and to evaluate the patient dose homogeneity for our TBI moving couch technique. Materials and Methods: Dosimetric data of 16 patients treated by TBI with moving couch and 6 MV were retrospectively analyzed. MOSFET dosimeters were calibrated against a Farmer chamber in a Perspex slab phantom and tested in an anthropomorphic phantom, under moving couch TBI conditions. Before treatment, a total body CT scan was acquired with the patient in treatment position. CT images were used to calculate the mid-line dose at 5 locations in the patient's body (head, neck, mediastinum, umbilicus and thigh), using Tissue-Phantom-Ratio (TPR) values according to the separation of each location and prescribed dose at mid-line of the umbilicus. Patient in-vivo dosimetry was performed during first fraction for all patients. Patient entrance dose was measured by MOSFETs at the same 5 locations, then converted to mid-line dose, and compared to calculated values. Patient dose homogeneity was assessed by the percent difference between mid-line values of doses and mid-line dose at the umbilicus, for measured and calculated values. Results: The mean percentage dose difference between measured and calculated values were: -2% ± 6.1% for head, 0.2% ± 9.5% for neck, 2.3% ± 8.8% for mediastinum, 1% ± 7% for umbilicus, and -2.9% ± 9.3% for thigh. A difference in dose of more than 10% was found in 14/16 (87.5%) measurements. Fig. 1 . Comparison between in-vivo measured dose and calculated dose at head, neck, mediastinum, umbilicus and thigh. Linear regression curves and correlation coefficients are specified. The reference curve shows equal measured and calculated doses. Fig. 2 .Histogram of the difference between in-vivo measured and calculated doses at head, neck, mediastinum, umbilicus and thigh. The interval of ± 5% is specified.
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Acceptable patient dose homogeneity within ±10% of the prescribed dose, as determined by in-vivo measurements, was achieved for 11/16 (68.7%) patients at head, 13/16 (81.2%) patients at neck, 13/16 (81.2%) patients at mediastinum, and 13/16 (81.2%) patients at thigh location. For 11/16 (68.7%) patients hose homogeneity was acceptable over the whole body. Table 1 . Comparison of patient dose homogeneity (defined by the percent difference between midline values of doses and midline dose at the umbilicus) between in-vivo measurement and calculation.
Conclusions:
If properly calibrated, MOSFETs are suitable for TBI in-vivo dosimetry. Moving couch technique for TBI enables acceptable patient dose homogeneity. Dose homogeneity can be improved by adding tissue compensators for head, neck and legs or by speed modulation.
